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Objective: To examine the association between hearing aids (HAs) and time to diagnosis of 
Alzheimer’s or dementia, anxiety or depression, and injurious falls among adults aged 66 and 
older within 3 years of hearing loss (HL) diagnosis.  
Design: Retrospective cohort study. 
Setting: We used 2008-2016 national longitudinal claims data (based on office-visit, inpatient, 
or outpatient healthcare encounters) from a large private payer. We used Kaplan Meier curves to 
examine unadjusted disease-free survival and crude and adjusted Cox regression models to 
examine associations between HAs and time to diagnosis of 3 age-related/HL-associated 
conditions within 3 years of HL diagnosis. All models were adjusted for age, sex, race/ethnicity, 
Census Divisions, and prior diagnosis of cardiovascular conditions, hypertension, 
hypercholesterolemia, obesity, and diabetes.  
Participants: 114,862 adults aged 66 and older diagnosed with HL. 
Measurement: Diagnosis of (1) Alzheimer’s disease or dementia; (2) depression or anxiety; and 
(3) injurious falls. 
Intervention: Use of HAs. 
Results: Large gender and racial/ethnic differences exist in HA use. Approximately 11.3% of 
women vs. 13.3% of men used HAs (95% CI Difference: -0.024, -0.016). About 13.6% of 
Whites (95% CI: 0.13, 0.14) vs. 9.8% of Blacks (95% CI: 0.09, 0.11) and 6.5% of Hispanics 
(95% CI: 0.06, 0.07) used HAs. The risk-adjusted hazard ratios of being diagnosed with 
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Alzheimer’s disease/dementia, anxiety/depression, and injurious falls within 3 years after HL 
diagnosis, for those who used HAs vs. those who did not, were 0.82 (95% CI: 0.76-0.89), 0.89 
(95% CI: 0.86-0.93), and 0.87 (95% CI: 0.80-0.95), respectively. 
Conclusions: Use of HAs is associated with delayed diagnosis of Alzheimer’s, dementia, 
depression, anxiety, and injurious falls among older adults with HL. Although we have shown an 
association between use of HA and reduced risk of physical and mental decline, randomized 
trials are needed to determine whether, and to what extent, the relationship is causal. 
  
This article is protected by copyright. All rights reserved.
 5 
Introduction 
More than 27 million Americans 65 years and older live with hearing loss (HL).1 
Prevalence of HL is estimated to grow due to our growing geriatric population.2 Prior literature 
indicates strong associations between HL and adverse conditions such as social isolation, 
depression,3,4 cognitive decline,5-7 injuries associated with falls,8 and reduced quality of life.9,10 
Despite these findings, use of hearing aids (HAs) as a potential treatment intervention for those 
with HL remains low.1 This has been attributed to multiple factors, including lack of perceived 
need, limited apparent benefit,1 uncomfortable fit, a complex system of hearing care with 
multiple points of contact,11 stigma,12 and cost13 (exacerbated by no or low insurance coverage in 
the U.S.).14  
There is a paucity of research on the impact of HAs on medical outcomes. Further, the 
results of these studies are often inconsistent. For example, Dawes et al. found no significant 
differences in cognitive and mental health outcomes between HA users and non-users.15 A cross-
sectional analysis of 164,770 adults ages 40 to 69 with HL in the UK found better cognitive 
function among those who used HAs compared with those who did not.16 A recent review of the 
literature17 by Hubbard et al. showed that hearing interventions have been successful in slowing 
the progression of cognitive decline among aging adults without dementia.18-20 Despite 
contradictory findings and lack of literature studying this population, evidence-based research on 
hearing interventions among older adults with HL is gaining momentum.17 More longitudinal 
research on this topic is warranted. 
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Although routine HL examinations and HA-related expenditures are not covered by 
Medicare fee-for-service, many managed care plans cover a portion of HA costs. Thus, we used 
nationwide claims data from a private managed care payer to examine the association between 
HA use and time to diagnosis of 3 common conditions among adults 66 years and older who 
were diagnosed with HL: (1) Alzheimer’s disease (AD) or dementia;7,21 (2) depression or 
anxiety;22,23 and (3) injuries related to falls.8,24 We hypothesized that HAs are associated with a 
delay in diagnosis of the above age-related conditions. 
Methods 
Data Source 
 This retrospective cohort study of adults with HL diagnoses defined in any patient care 
setting used a national, private insurance claims database, Clinformatics® DataMart Database 
(OptumInsight, Eden Prairie, MN). This de-identified claims database captures all emergency 
department (ED), outpatient, and inpatient encounters of over 79 million adults and children who 
were commercially insured by a single, large U.S. private payer and who had both medical and 
pharmacy coverage throughout their enrollment. The study was deemed exempt by the 
Institutional Review Board (IRB) at the researchers’ institution.  
Patient Selection 
The study period covered 2008 to 2016. Using all private payer claims data between 
January 1, 2008 and December 31, 2013, adults age >= 66 years with ICD-9-CM, International 
Classification of Diseases, 9th Revision, Clinical Modification, diagnosis codes for HL were 
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identified (Table S1). Diagnosis of HL is usually done by an audiologist. To identify patients 
with incident HL, those with HL diagnoses or HA procedure codes within one year prior to the 
incident HL were excluded (Table S2). Additional exclusion criteria included (1) fewer than 12 
months of continuous enrollment prior to index HL diagnosis, (2) pre-existing diagnosis of 
dementia, AD, anxiety, depression, and a fall leading to injury within 12 months prior to the 
index HL diagnosis (Table S3);25,26 and (3) not having at least 3 years of continuous enrollment 
after the index HL. Figure 1 depicts the final sample size. 
Dependent and Explanatory Variables  
Outcomes included being diagnosed with AD or dementia, depression or anxiety, and 
injurious fall, as determined by ICD-9 and ICD-10 codes. The difference in days for the time to 
the outcome was calculated by identifying the first claim service date with any diagnosis of the 
three outcome conditions in the 3-year period following the index HL. Baseline demographic 
characteristics included age, sex, race and ethnicity, and U.S. Census Division (New England, 
Mid Atlantic, East North Central, West North Central, South Atlantic, East South Central, West 
South Central, Mountain, Pacific) at the time of HL diagnosis. Comorbidities for risk adjustment 
included hypertension (non-gestational), diabetes (non-gestational), obesity, cardiovascular 
conditions, and hypercholesterolemia in the 12 months prior to HL diagnosis. These conditions 
were chosen because of their higher prevalence among people with HL.27 
Statistical Analysis  
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Bivariate analyses of baseline demographic characteristics and comorbid conditions at the 
time of HL diagnosis were conducted for HA users and non-users. For categorical variables, 
bivariate analysis was conducted using Chi-Square testing, and 95% confidence intervals for 
differences in proportions were calculated. For continuous variables, means and standard 
deviations were calculated and their distributions were examined to ensure robustness of 
parametric T-tests.  
To examine disease-free survival of HA users versus non-users, Kaplan-Meier product-
limit survival curves were constructed for each outcome. Log-Rank tests were applied to 
examine the proportional hazards assumption and to test for differences in survival curves. 
Patients were right censored if they did not experience the outcome in the 3-year follow-up 
period. Cox proportional hazards regression models were developed to calculate unadjusted and 
risk adjusted hazard ratios to measure the effect of HA use on each outcome. 
Additionally, state-level variation in incidence rates of outcomes was assessed by 
calculating the state-specific unadjusted rates over the entire timeframe of 2008-2016. All states 
were ranked and split into tertiles based on their unadjusted incident rates of HA use and the 
three outcomes. To examine the hypothesized effect of state-specific HA utilization on each 
outcome, a Pearson’s correlation coefficient was calculated. To assess geographic variation, 
state-level heat maps were developed and divided into tertiles. The strength of the association of 
HA utilization and outcomes was measured via Pearson’s correlation coefficients (Figure S1 and 
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Table S4). All analyses were conducted using SAS 9.4 (SAS Institute Inc., Cary, NC, USA). 
Statistical testing was two-tailed, with a 0.05 significance level.  
Sensitivity Analysis 
 The effect of selection bias was examined by performing propensity score matching using 
multivariable logistic regression adjusting for the following observable confounders: age, sex, 
U.S. Census Division, and clinically relevant medical conditions. We used a caliper matching 
algorithm is caliper size of 0.001 with a 1:1 ratio of hearing aid users (cases) to controls (hearing 
aid non-users) without replacement. After propensity score matching, Cox regression models 
were fit with HA as the main effect to estimate hazard ratios for each outcome. The results did 
not appreciably change (Table S5). Therefore, main results are presented without propensity 
matching. 
Results 
In a sample of 114,862 adults aged 66 or older diagnosed with HL, 14,109 (12.3%) used 
HAs (Table 1). The mean (SD) age was 75.8 (5.8) years, with no significant difference between 
those with and without HAs. Approximately 11.3% of female vs. 13.3% of males (diff: 2.0%; 
95% CI, -0.0237, -0.0161) had HAs, along with 13.6% of whites vs. 9.8% of Blacks (diff: 3.8%; 
95% CI: 0.0300, 0.0451) and 6.5% of Hispanics (diff: 7.1%; 95% CI: 0.0653, 0.0760) (p < 
0.0001 for all). Among the 9 U.S. Census Divisions, the highest level of HA use (36.9%) was in 
the West North Central Division (Iowa, Kansas, Minnesota, Missouri, Nebraska, North 
Dakota and South Dakota). The lowest (5.9%) was in the Mountain Division (Idaho, Montana, 
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Wyoming, Nevada, Utah, Colorado, Arizona, New Mexico)(p < 0.0001). On average, the 
prevalence of hypertension (24.4% vs. 21.6%; p<0.0001), hypercholesterolemia (47.9% vs 
44.4%; p<0.0001), and diabetes (17.9% vs. 15.5% (p<0.0001) were higher among patients 
without HAs compared with those with HAs.   
Figure 2 shows the unadjusted hazard ratios for diagnosis of each outcome within a 3-
year period. For all 3 outcomes, HA users had lower hazard ratios than non-HA users: AD or 
dementia (0.83; 95% CI:0.77-0.89), depression or anxiety (0.86; 95% CI: 0.83-0.90), and 
injurious fall (0.87; 95% CI:0.80-0.93).   
Kaplan-Meier curves in Figure 3 also indicate delays in diagnosis of the three outcomes 
among adults with HL who used HAs compared with those who did not. Within 3 years of HL 
diagnosis, a higher percentage remained free of a diagnosis of AD or dementia (96.6% vs. 
96.1%), depression or anxiety (83.5% vs. 81.6%), or a fall (94.9% vs. 94.2%). 
The risk adjusted hazard ratio for developing AD or dementia within 3 years of being 
diagnosed with HL was lower by 0.82 (95% CI: 0.76-0.89) among those who used HAs than 
those who did not. For depression or anxiety, it was lower by 0.89 (95% CI: 0.86-0.93). For 
injurious falls, it was lower by 0.87 (95% CI: 0.80-0.95) (Table 2). The estimated models and 
corresponding hazard ratios are reported in supplemental materials (Tables S6-S9).  
Correlations between HA use and the 3 outcomes were also examined at the state level. 
The heat maps in Figures S1 depict substantial geographic clustering among the 52 states in 
incidence rates of HA use and the 3 outcomes. For example, the incidence of HA use in the 
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majority of Pacific Division states (i.e. Oregon, Washington, California) was lower than in West-
North-Central states (i.e. Minnesota, Iowa, Missouri). Conversely, the incidence of AD and 
dementia, and anxiety and depression were higher in Pacific states compared with West North 
Central states. State-level Pearson correlation coefficients did not indicate significant correlation 
between HA use and the 3 outcomes (Table S4). 
Discussion 
In a large national database of insurance claims, use of HAs among adults with HL was 
associated with a significantly lower risk of being diagnosed with AD or dementia, depression or 
anxiety, and injurious falls. We also found significant racial/ethnic and gender disparities in use 
of HAs.  
By providing enhanced hearing input, HAs may facilitate greater social engagement, 
lower levels of effort to recognize sounds and speech, lower levels of depression or anxiety 
symptoms, higher levels of physical balance, and greater feelings of independence and self-
efficacy.28-31 Believing in one’s physical and cognitive ability to socially engage and accomplish 
a task or participate in social events has been shown to advance cognitive measurements. In 
contrast, isolation and depression are independently associated with AD and dementia-related 
illnesses.32,33 Despite evidence related to the positive association between HA use and 
improvement in quality of life and well-being, prior studies have reported conflicting results 
regarding the preventative role of HAs in age-related conditions.15,34-37 
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The present findings support previous literature on substantial gender and racial/ethnic 
disparities in the use of HAs.12,34,38 The underlying factors behind these disparities have been 
discussed extensively.39,40 Our findings are unique because they underscore the importance of 
protective associations of HA with each of our conditions that are more common among females 
and minorities. For example prevalence of AD or dementia41,42 and anxiety or depression42,43 are 
substantially higher among females than males as well as among African Americans compared to 
Caucasians. It follows that reducing disparities in access and use of HAs is likely attributable to 
insurance coverage and affordability among these subpopulations. It is also conceivable that 
other salient factors, such as severity of hearing loss, frailty, socioeconomic status, lifestyle and 
behavior choices are associated with diagnosis of age-related conditions. 
Mounting evidence indicates strong associations between HL and cognitive decline and 
increased risk of falls among older adults.5,15,44,45 Two main theories explain this association: (1) 
cascade theory and (2) common cause theory.46,47 The cascade theory hypothesizes that extended 
periods of uncorrected HL cause more isolation and less stimulation, which may lead to 
cognitive decline among older adults.47 The common cause theory hypothesizes that both HL and 
physical and cognitive decline are associated with aging changes in the nervous system, meaning 
that both are part of the normal aging process.48  
Our findings corroborate existing literature asserting that use of HAs is associated with 
lower risk of being diagnosed with AD or dementia, anxiety or depression, and falls.49 Recent 
studies found hearing interventions to be protective against further cognitive decline among older 
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adults with dementia. For example, Maharani et al. found reduced rates of decline in episodic 
memory scores among older adults with HL and dementia after they started using HAs.50 
Prolonged sensory deprivation due to hearing or vision loss has been linked to social isolation, 
delirium, and cognitive decline.51 Our findings posit additional evidence that HL may be a 
modifiable risk factor (through HA intervention) for AD or dementia. 
 Additionally, HL has been linked with depression and anxiety.32 People at greater risk of 
isolation because of functional or sensory impairments are prone to experience depression. Our 
results suggest that HAs may delay diagnosis of depression and anxiety among individuals with 
HL. While improvement in one-to-one and group conversations in various social and healthcare 
settings is important, HA use also confers improvements in independently accomplishing tasks, 
work productivity, self-awareness, self-confidence, and self-advocacy.  
 Age-related HL is negatively associated with balance function and increases the risk of 
fall-related injuries.52,53 Plausibly, this could be explained by poorer spatial awareness or 
cognitive overload resulting from auditory deprivation among adults with HL. A decline in the 
ability to notice auditory cues may lead to lower awareness of one’s surroundings and thus to 
higher incidence of falls.8  
Currently, there is no standard estimate of incidence or prevalence for each of the 
outcomes in our study. Depending upon the data source, there can be vastly different prevalence 
and incidence estimates. For instance, the Health and Retirement Study linked to Medicare 
administrative claims data has shown that cognitive test results from survey data versus 
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diagnoses from claims data can yield very different incidence for dementia.54 For example, 
among Whites, incidence of dementia based on cognitive tests from surveys was lower than that 
using diagnosis codes from claims (3.2% versus 12.3%).54 In contrast, among Blacks, dementia 
incidence was higher using cognitive tests compared to that using diagnosis codes (15.2% vs. 
11.1%).54 
Prior literature shows incidence for dementia, injurious falls, and depression in the 
general geriatric population is 12.2%,54 7.5%,55 and 25.2%,56 respectively. In support of previous 
literature, our findings indicate higher incidence of these conditions among hearing loss patients. 
From 2008-2016, we found incidence of dementia, injurious falls, and depression for hearing 
loss patients to be 13.9%, 12.7%, and 35.6%, respectively.  
It is important to note that on average HAs cost between $2,000-$7,000 and are not 
covered (or are underinsured) by most health plans, which shifts the financial burden of HAs to 
patients.40 Today, more than 27 million older Americans live with HL, but only about 14% of 
them use HAs.1 While cost is a pertinent and plausible barrier to access to HAs, efforts have 
been made to improve access. The US PCAST57 report asserts that the HA prescription process 
should be made similar to that for eyeglasses and contact lenses. Furthermore, the Over-the-
Counter Hearing Aid Act58 enables availability of hearing aids over the counter without a 
prescription. Although HAs are expensive, the medical costs of many conditions that could be 
prevented or delayed by using HAs are substantially more expensive. For example, in 2017, the 
annual incidence rate of AD among Americans aged 65 years or older was 480,000 patients; by 
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2050, this is expected to rise to approximately 1 million patients.41 Average annual direct 
healthcare payments (in 2016 dollars) are $46,000 for each patient with AD alone 
(approximately $34,000 more than direct healthcare spending for those without AD).41 Any 
delay in diagnosis of AD or dementia could not only lead to large cost savings, but also improve 
the health and well-being of older adults.  
Limitations 
 
 Our study has a number of potential limitations. First, inherent limitations of using claims 
data include a lack of information about patients’ socioeconomic status, lifestyle choices, 
educational attainment, and other salient factors. While appropriate use of HAs might delay the 
diagnosis of age-related conditions, HA users could have different lifestyle choices and resources 
available to them that could also contribute to a delayed diagnosis of these conditions. Second, 
since we use claims and diagnostic codes to define HL, we may be unable to identify all patients 
with HL. HL patients without official diagnoses may not be included; others may have been 
incorrectly included as new patients if their diagnosis preceded the 12-month look-back period. 
Furthermore, claims data do not include direct audiometric measurements of HL. We were able 
to identify those who were diagnosed with HL but could not determine HL severity. We assumed 
that the majority of adults aged 66 and older who were diagnosed with HL had moderate to 
severe HL, and thus were in need of HAs. Third, we did not have any way to measure frequency 
and duration of HA use, if any, among individuals who purchased HAs. Often HAs are not fitted 
properly, and people do not use their HAs consistently.14 There are also cultural taboos among 
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many subpopulations such as minorities and females regarding the use of HAs. Individuals with 
HL may purchase HAs on the advice of physicians or family members, but rarely use them. 
Fourth, analysis of falls is complex. Using claims data, we controlled for no history of fall-
related injuries during the 12-month period before index hearing-loss diagnosis but were not able 
to control for other fall-related factors. Finally, our data came from a private insurance database 
which might introduce biases into our findings associated with the health status and higher 
functioning of Medicare Managed Care patients. Furthermore, state-level market penetration 
from a single large private payer varies; therefore, in the absence of sampling weights, national 
prevalence is not estimable at this time 
The study’s strengths include having a large sample size due to using claims data, which 
contain large sample sizes and longitudinal follow up of health services and provide a broad 
clinical perspective on health outcomes over time. Since HAs are not covered by Medicare fee-
for-service, this covers an important segment of the population that likely has at least some 
coverage for HAs. Therefore, we examined a reasonably exhaustive snapshot of their service 
utilization.  
To ensure the absence of prior diagnosis of our outcomes, a one-year clean period was 
used as a sufficient amount of time to ensure no pre-existing diagnoses. This enabled us to 
measure the association between HAs and time-to-diagnosis of 3 conditions within 3 years of HL 
diagnosis, controlling for confounding demographics and comorbidities.   
Conclusion 
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Use of HAs among adults with HL was associated with delay or prevention of 3 common and 
important age-related conditions: AD or dementia, depression or anxiety, and fall-related 
injuries. Timely diagnosis of HL and early use of HAs may delay the diagnosis of cognitive 
decline and reduce the risk of injurious falls. 
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Figure 1. Schematic Flow Diagram of the Sample Size 
Note: The study period covered 2008 to 2016. We identified adults age >= 66 years of age with 
ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification, 
diagnosis codes for hearing loss between January 1, 2008 and December 31, 2013. 
 
Figure 2. Unadjusted Hazard Ratios for Developing Age-Related Conditions Among Adults 
with Hearing Loss Who Used Hearing Aids Compared with Those Who Did Not 
Note: Unadjusted hazard ratios and 95% confidence intervals were determined using Cox 
proportional hazards regression models with hearing aid use as the covariate. 
 
Figure 3. Kaplan-Meier Curves: Disease-free Time in Days to the Diagnosis of Three Age-
Related Conditions 
Notes: 
(1) All adults in the cohort had no diagnosis of Alzheimer’s or dementia, anxiety or depression, 
or falls on a claim for one year prior to the index diagnosis of hearing loss.  (2) All log rank tests 
were significant at the 0.05 level.  
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Table S7. Cox Regression Results for Anxiety or Depression 




Figure S1. Heat Maps of Incidence Rates of Hearing Aid Use, Alzheimer’s disease and/or 
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Table 1. Descriptive Characteristics of People 66 Years or Older with Hearing Loss with and Without 
Hearing Aids* 





Variables N=114,862 N=100,753 N=14,109  
Age:    <0.0001 
  66-70  28,685 (25.0%) 25,248 (88.0%) 3,437 (12.0%)  
  71-75  27,126 (23.6%) 23897 (88.1%) 3229 (11.9%)  
  76-80 24,553 (21.4%) 21615 (88.0%) 2938 (12.0%)  
  80+ 34,498 (30.0%) 29993 (86.9%) 4505 (13.1%)  
Gender:    <0.0001 
   Female 57885 (50.4%) 51338 (88.7%) 6547 (11.3%)  
   Male 56958 (49.6%) 49397 (86.7%) 7561 (13.3%)  
   Unknown           19 (0.02%)          18 (94.7%)          1 (   5.0%)  
Race:    <0.0001 
   White 83,185 (72.4%) 71,887(86.4%) 11,298 (13.6%)  
   Black 6,688 (5.8%) 6,031 (90.2%) 657 (9.8%)  
   Hispanic 10,236 (8.9%) 9,570 (93.5%) 666 (6.5%)  
   Asian 3,741 (3.3%) 3,429 (91.6%) 312 (8.3%)  
   Unknown/Missing 11,012 (10%%) 9,836 (89.3%) 1,176 (10.7%)  
Census Divisions+:    <0.0001 
   New England 4,843 (4.2%) 4,472 (92.3%) 371 (7.7%)  
   Middle Atlantic 6,803 (5.9%) 6,330 (93.1%) 473 (6.9%)  
   East North Central 10,011 (8.7%) 9,015 (90.1%) 996 (9.9%)  
   West North Central 15,810 (13.8%) 9,980 (63.1%) 5,830 (36.9%)  
   South Atlantic 20,718 (18.0%) 18,474 (89.2%) 2,244 (10.8%)  
   East South Central 2,650 (2.3%) 2,498 (94.3%) 152 (5.7%)  
   West South Central 11,512 (10.0%) 10,633 (92.4%) 879 (7.6%)  
   Mountain 14,590 (12.7%) 13,734 (94.1%) 856 (5.9%)  
   Pacific 26,236 (22.8%) 24,046 (91.7%) 2,190 (8.3%)  
   Unknown or Puerto Rico 1,689 (1.5%) 1,571 (93.0%) 118 (7.0%)  
Chronic Conditions:    <0.0001 
  Cardiovascular 39,518 (34.4%) 34,690 (34.4%) 4,828 (34.2%)  
  Hypertension (complicated) 27,602 (24.0%) 24,558 (24.4%) 3,044 (21.6%)  
  Hypercholesterolemia 54,544 (47.5%) 48,284 (47.9%) 6,260 (44.4%)  
  Obesity 16,703 (14.5%) 14,714 (14.6%) 1,989 (14.1%)  
  Diabetes (complicated) 20,197 (17.6%) 18,016 (17.9%) 2,181 (15.5%)  
*Significance testing for age was performed using a t-test, and Chi-Square tests at an alpha = 0.05 were used for all 
categorical variables. 
+ Census Division: New England(Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut); Middle 
Atlantic(New York, Pennsylvania, New Jersey); East North Central(Wisconsin, Michigan, Illinois, Indianan, Ohio); West 
North Central(North Dakota, South Dakota, Nebraska, Kansas, Minnesota, Iowa, Missouri); South Atlantic(Delaware, 
Maryland, District of Columbia, Virginia, West Virginia, North Carolina, South Carolina, Georgia, Florida); East South 
Central(Kentucky, Tennessee, Mississippi, Alabama); West South Central(Oklahoma, Texas, Arkansas, Louisiana); 
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Mountain(Idaho, Montana, Wyoming, Nevada, Utah, Colorado, Arizona, New Mexico); Pacific(Alaska, Washington, 
Oregon, California, Hawaii). 
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Table 2. Crude and Adjusted Hazard Ratios (HR) with 95% Confidence Intervals for Diagnosis of Age-Related Conditions 




Crude HR P-Value Adjusted HR P-Value 
Alzheimer’s or 
Dementia 
0.826 (0.765, 0.891) <0.001 0.824 (0.761, 0.893) <0.001 
     
Anxiety or 
Depression 
0.863 (0.827, 0.900) <0.001 0.894 (0.856, 0.934) <0.001 
     
Falls 0.865 (0.801, 0.934) <0.001 0.871 (0.804, 0.945) <0.001 
 
*Crude hazard ratios and 95% confidence intervals were estimated with hearing aid use as the 
primary exposure variable.  
**Adjusted hazard ratios and 95% confidence intervals were calculated using Cox proportional 
hazards regression models for age, gender, U.S. Census Division, hypertension, diabetes, 
hypercholesterolemia, obesity, and cardiovascular conditions (see Tables S6-S9).  
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